<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173379</url>
  </required_header>
  <id_info>
    <org_study_id>10-392 C</org_study_id>
    <nct_id>NCT02173379</nct_id>
  </id_info>
  <brief_title>Absorb IV Randomized Controlled Trial</brief_title>
  <official_title>A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ABSORB IV is a prospective, randomized (1:1, Absorb BVS to XIENCE), single-blind,&#xD;
      multi-center study, registering approximately 2610 subjects from approximately 140 sites in&#xD;
      the United States and outside the United States. ABSORB IV is a continuation of ABSORB III&#xD;
      (NCT01751906) trial which are maintained under one protocol because both trial designs are&#xD;
      related. The data from ABSORB III and ABSORB IV will be pooled to support the ABSORB IV&#xD;
      primary endpoint. Both the trials will evaluate the safety and effectiveness of Absorb BVS.&#xD;
&#xD;
      The ABSORB IV Randomized Controlled Trial (RCT) is designed to continue to evaluate the&#xD;
      safety and effectiveness as well as the potential short and long-term benefits of Abbott&#xD;
      Vascular Absorb™ Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System&#xD;
      (once commercially available), as compared to the commercially approved, control stent&#xD;
      XIENCE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ABSORB IV:&#xD;
&#xD;
      A. Primary Objective:&#xD;
&#xD;
        -  To evaluate 30-day clinical outcomes of the Absorb BVS compared to XIENCE in the&#xD;
           treatment of subjects with ischemic heart disease caused by up to three de novo native&#xD;
           coronary artery lesions in a maximum of two epicardial vessels, with a maximum of two&#xD;
           lesions per epicardial vessel.&#xD;
&#xD;
        -  To evaluate long-term clinical outcomes of Absorb BVS compared to XIENCE in the&#xD;
           treatment of subjects with ischemic heart disease caused by up to three denovo native&#xD;
           coronary artery lesions in a maximum of two epicardial vessels, with a maximum of two&#xD;
           lesions per epicardial vessel.&#xD;
&#xD;
      B. Secondary Objectives:&#xD;
&#xD;
        -  To evaluate 1-year clinical outcomes of the Absorb BVS compared to XIENCE in the&#xD;
           treatment of subjects with ischemic heart disease caused by up to three de novo native&#xD;
           coronary artery lesions in a maximum of two epicardial vessels, with a maximum of two&#xD;
           lesions per epicardial vessel.&#xD;
&#xD;
        -  To evaluate the incidence of angina occurring within 1 year, with treatment of Absorb&#xD;
           BVS compared to XIENCE.&#xD;
&#xD;
      The enrollment of the 2610 subjects in ABSORB IV will start after enrollment completion of&#xD;
      the 2000 primary analysis subjects in ABSORB III. All registered subjects will have clinical&#xD;
      follow-up at 30, 90, 180, 270 days and 1, 2, 3, 4 and 5 years.&#xD;
&#xD;
      Note: All registered subjects in ABSORB IV will be followed up to 5 years via telephone&#xD;
      contact/office visit if it is necessary as determined by the Sponsor.&#xD;
&#xD;
      In addition, all 2610 subjects in ABSORB IV will complete patient-reported outcome (PRO)&#xD;
      self-administered questionnaires at baseline, 30 days,180 days, 1 year, 3 years and 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Target Lesion Failure (TLF)</measure>
    <time_frame>30 days</time_frame>
    <description>Target lesion failure (TLF) composite of Cardiac Death, Myocardial Infarction attributable to Target Vessel (TV-MI), or Ischemia-Driven Target Lesion Revascularization (ID-TLR))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TLF at 1-year, Non-inferiority Against the Control</measure>
    <time_frame>1 year</time_frame>
    <description>One-sided p-value by using Farrington-Manning non-inferiority test will be used with non-inferiority margin of 4.8%, to be compared with a one-sided significance level of 0.025.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina at 1-year, Non-inferiority Against the Control</measure>
    <time_frame>1 year</time_frame>
    <description>Angina is defined as any angina or angina equivalent symptoms determined by the physician and/or research coordinator after interview of the patient, and as adjudicated by a clinical events committee (CEC).&#xD;
This analysis will exclude angina or angina equivalent symptoms that occurred following the index procedure through hospital discharge or 7 days, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Target Lesion With Acute Success- Device Success (Lesion Level Analysis)</measure>
    <time_frame>In-hospital (≤ 7days)</time_frame>
    <description>Successful delivery and deployment of the study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 30% by quantitative coronary angiography (QCA) (by visual estimation if QCA unavailable). When bailout scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment is not one of the criteria for device success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Success- Procedural Success (Subject Level Analysis)</measure>
    <time_frame>In-hospital (≤ 7days)</time_frame>
    <description>Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>30 days</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>90 days</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>180 days</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>270 days</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>1 year</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>2 years</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>4 years</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>5 years</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>30 days</time_frame>
    <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>90 days</time_frame>
    <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>180 days</time_frame>
    <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>270 days</time_frame>
    <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>1 year</time_frame>
    <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>2 years</time_frame>
    <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>3 years</time_frame>
    <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>4 years</time_frame>
    <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction (MI)</measure>
    <time_frame>5 years</time_frame>
    <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</measure>
    <time_frame>30 days</time_frame>
    <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</measure>
    <time_frame>90 days</time_frame>
    <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</measure>
    <time_frame>180 days</time_frame>
    <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</measure>
    <time_frame>270 days</time_frame>
    <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</measure>
    <time_frame>1 year</time_frame>
    <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</measure>
    <time_frame>2 year</time_frame>
    <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</measure>
    <time_frame>3 years</time_frame>
    <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</measure>
    <time_frame>4 years</time_frame>
    <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</measure>
    <time_frame>5 years</time_frame>
    <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>30 days</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants withTarget Lesion Revascularization (TLR)</measure>
    <time_frame>90 days</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>180 days</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>270 days</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>1 year</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>2 years</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>3 years</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>4 years</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>5 years</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia Driven TLR (ID-TLR)</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia Driven TLR (ID-TLR)</measure>
    <time_frame>30 days</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia Driven TLR (ID-TLR)</measure>
    <time_frame>90 days</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia Driven TLR (ID-TLR)</measure>
    <time_frame>180 days</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia Driven TLR (ID-TLR)</measure>
    <time_frame>270 days</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia Driven TLR (ID-TLR)</measure>
    <time_frame>1 year</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia Driven TLR (ID-TLR)</measure>
    <time_frame>2 years</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia Driven TLR (ID-TLR)</measure>
    <time_frame>3 years</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia Driven TLR (ID-TLR)</measure>
    <time_frame>4 years</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia Driven TLR (ID-TLR)</measure>
    <time_frame>5 years</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>30 days</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>90 days</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>180 days</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. classified as: Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
-TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>270 days</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>1 year</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>2 years</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>3 years</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>4 years</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>5 years</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ID-TVR Excluding TLR</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ID-TVR Excluding TLR</measure>
    <time_frame>30 days</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ID-TVR Excluding TLR</measure>
    <time_frame>90 days</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ID-TVR Excluding TLR</measure>
    <time_frame>180 days</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ID-TVR Excluding TLR</measure>
    <time_frame>270 days</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ID-TVR Excluding TLR</measure>
    <time_frame>1 year</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ID-TVR Excluding TLR</measure>
    <time_frame>2 years</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ID-TVR Excluding TLR</measure>
    <time_frame>3 years</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ID-TVR Excluding TLR</measure>
    <time_frame>4 years</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ID-TVR Excluding TLR</measure>
    <time_frame>5 years</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>30 days</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>90 days</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>180 days</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>270 days</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>1 year</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>2 years</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>3 years</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>4 years</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>5 years</time_frame>
    <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced All Death/All MI</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced All Death/All MI</measure>
    <time_frame>30 days</time_frame>
    <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced All Death/All MI</measure>
    <time_frame>90 days</time_frame>
    <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced All Death/All MI</measure>
    <time_frame>180 days</time_frame>
    <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced All Death/All MI</measure>
    <time_frame>270 days</time_frame>
    <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced All Death/All MI</measure>
    <time_frame>1 year</time_frame>
    <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced All Death/All MI</measure>
    <time_frame>2 years</time_frame>
    <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced All Death/All MI</measure>
    <time_frame>3 years</time_frame>
    <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced All Death/All MI</measure>
    <time_frame>4 years</time_frame>
    <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced All Death/All MI</measure>
    <time_frame>5 years</time_frame>
    <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>30 days</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>90 days</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>180 days</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>270 days</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>1 year</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>2 years</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>4 years</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI</measure>
    <time_frame>5 years</time_frame>
    <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>30 days</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>90 days</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>180 days</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>270 days</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>1 year</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>2 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>3 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>4 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>5 years</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE)</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced With Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>30 days</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>90 days</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>180 days</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>270 days</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>1 year</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>2 years</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>3 years</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>4 years</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</measure>
    <time_frame>5 years</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (Target Vessel Failure, TVF)</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</measure>
    <time_frame>30 days</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</measure>
    <time_frame>90 days</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</measure>
    <time_frame>180 days</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</measure>
    <time_frame>270 days</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</measure>
    <time_frame>1 year</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</measure>
    <time_frame>2 years</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</measure>
    <time_frame>3 years</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</measure>
    <time_frame>4 years</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</measure>
    <time_frame>5 years</time_frame>
    <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>30 days</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>90 days</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>180 days</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>270 days</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>1 year</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>2 years</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>3 years</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>4 years</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>5 years</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Scaffold/Stent Thrombosis (Per Academic Research Consortium (ARC) Definition)</measure>
    <time_frame>0 - 24 hours post stent implantation</time_frame>
    <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Subacute Scaffold/Stent Thrombosis (Per ARC Definition)</measure>
    <time_frame>&gt;24 hours - 30 days post stent implantation</time_frame>
    <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Late Scaffold/Stent Thrombosis (Per ARC Definition)</measure>
    <time_frame>30 days - 1 year post stent implantation</time_frame>
    <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cumulative Scaffold/Stent Thrombosis (Per ARC Definition)</measure>
    <time_frame>0 to 730 Days</time_frame>
    <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rehospitalization</measure>
    <time_frame>30 days</time_frame>
    <description>Coronary artery disease (CAD) related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rehospitalization</measure>
    <time_frame>90 days</time_frame>
    <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rehospitalization</measure>
    <time_frame>180 days</time_frame>
    <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rehospitalization</measure>
    <time_frame>270 days</time_frame>
    <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rehospitalization</measure>
    <time_frame>1 year</time_frame>
    <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rehospitalization</measure>
    <time_frame>2 years</time_frame>
    <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rehospitalization</measure>
    <time_frame>3 years</time_frame>
    <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rehospitalization</measure>
    <time_frame>4 years</time_frame>
    <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rehospitalization</measure>
    <time_frame>5 years</time_frame>
    <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>270 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Repeat Coronary Arteriography</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Landmark Analysis on MACE and TVF and Their Components</measure>
    <time_frame>3-4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Landmark Analysis on MACE and TVF and Their Components</measure>
    <time_frame>3-5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</measure>
    <time_frame>3-4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</measure>
    <time_frame>3-5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Failure (TLF)</measure>
    <time_frame>1 year</time_frame>
    <description>The analysis will be based on 4610 subjects (2000 primary analysis subjects of ABSORB III and 2610 subjects of ABSORB IV)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>Baseline</time_frame>
    <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.&#xD;
The following questionnaires will be used in this study:&#xD;
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life&#xD;
EuroQoL 5D (EQ-5D) survey to assess overall health status&#xD;
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)&#xD;
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.&#xD;
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>1 month</time_frame>
    <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.&#xD;
The following questionnaires will be used in this study:&#xD;
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life&#xD;
EuroQoL 5D (EQ-5D) survey to assess overall health status&#xD;
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)&#xD;
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.&#xD;
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>6 months</time_frame>
    <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.&#xD;
The following questionnaires will be used in this study:&#xD;
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life&#xD;
EuroQoL 5D (EQ-5D) survey to assess overall health status&#xD;
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)&#xD;
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.&#xD;
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>1 year</time_frame>
    <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.&#xD;
The following questionnaires will be used in this study:&#xD;
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life&#xD;
EuroQoL 5D (EQ-5D) survey to assess overall health status&#xD;
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)&#xD;
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.&#xD;
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>3 years</time_frame>
    <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.&#xD;
The following questionnaires will be used in this study:&#xD;
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life&#xD;
EuroQoL 5D (EQ-5D) survey to assess overall health status&#xD;
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)&#xD;
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.&#xD;
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes (PRO)</measure>
    <time_frame>5 years</time_frame>
    <description>Patient-reported outcomes (PRO) are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.&#xD;
The following questionnaires will be used in this study:&#xD;
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life&#xD;
EuroQoL 5D (EQ-5D) survey to assess overall health status&#xD;
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)&#xD;
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.&#xD;
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
  </other_outcome>
  <other_outcome>
    <measure>Landmark Analysis on TLF and Components</measure>
    <time_frame>3-4 years</time_frame>
    <description>TLF is defined as composite of Cardiac Death, Myocardial Infarction (MI) attributable to Target Vessel (TV-MI), or Ischemia- Driven Target Lesion Revascularization (ID-TLR).</description>
  </other_outcome>
  <other_outcome>
    <measure>Landmark Analysis on TLF and Components</measure>
    <time_frame>3-5 years</time_frame>
    <description>TLF is defined as composite of Cardiac Death, Myocardial Infarction (MI) attributable to Target Vessel (TV-MI), or Ischemia- Driven Target Lesion Revascularization (ID-TLR).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2604</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Stenosis</condition>
  <condition>Coronary Disease</condition>
  <condition>Coronary Stenosis</condition>
  <arm_group>
    <arm_group_label>Absorb BVS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XIENCE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) and XIENCE ProX (outside of the US only)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Absorb BVS</intervention_name>
    <description>Scaffold diameters: 2.5, 3.0 and 3.5 mm&#xD;
Scaffold lengths: 8, 12, 18, and 28 mm. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.&#xD;
Once Absorb GT1™ BVS System is commercially available, it can also be used in the ABSORB IV trial. Scaffold diameters: 2.5, 3.0 and 3.5 mm of and scaffold lengths: 8, 12, 18, 23, and 28 mm.&#xD;
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.&#xD;
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
    <arm_group_label>Absorb BVS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE</intervention_name>
    <description>Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).&#xD;
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm. The 3.25 mm is only available for XIENCE Xpedition&#xD;
Stent lengths: 8, 12, 15, 18, 23, and 28 mm&#xD;
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices&#xD;
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.</description>
    <arm_group_label>XIENCE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be at least 18 years of age.&#xD;
&#xD;
          2. Subject or a legally authorized representative must provide written Informed Consent&#xD;
             prior to any study related procedure, per site requirements.&#xD;
&#xD;
          3. Subject must have evidence of myocardial ischemia (e.g., silent ischemia, stable or&#xD;
             unstable angina, non-ST-segment elevation MI (NSTEMI), OR recent ST-segment elevation&#xD;
             MI (STEMI). Patients with stable coronary syndromes can be enrolled any time after&#xD;
             symptom onset if eligibility criteria are otherwise met. Patients with acute coronary&#xD;
             syndrome can be enrolled under the following conditions:&#xD;
&#xD;
               1. Unstable angina or NSTEMI within 2 weeks of the index procedure.&#xD;
&#xD;
               2. STEMI &gt; 72 hours ≤ 2 weeks prior to the index procedure.&#xD;
&#xD;
             Note: Subjects with Unstable angina (UA) or NSTEMI or STEMI occurring &gt; 2 weeks of the&#xD;
             index procedure can be included in the trial but should be categorized based on their&#xD;
             current angina class.&#xD;
&#xD;
          4. Subjects must be suitable for PCI. Subjects with stable angina or silent ischemia and&#xD;
             &lt; 70% diameter stenosis must have objective signs of ischemia as determined by one of&#xD;
             the following: abnormal stress echocardiogram, nuclear scan, electrocardiogram (ECG),&#xD;
             positron emission tomography (PET), magnetic resonance imaging (MRI), and/or&#xD;
             fractional flow reserve (FFR).&#xD;
&#xD;
             (Note: subject with silent ischemia must have a prior history of typical angina,&#xD;
             angina-equivalent symptoms, or atypical angina within the past year to be included in&#xD;
             the trial.)&#xD;
&#xD;
          5. Subject must be an acceptable candidate for coronary artery bypass graft (CABG)&#xD;
             surgery.&#xD;
&#xD;
          6. Female subject of childbearing potential who does not plan pregnancy for up to 1 year&#xD;
             following the index procedure. For a female subject of childbearing potential a&#xD;
             pregnancy test must be performed with negative results known within 7 days prior to&#xD;
             the index procedure per site standard.&#xD;
&#xD;
          7. Female subject is not breast-feeding at the time of the screening visit and will not&#xD;
             be breast-feeding for at least 1 year following the index procedure.&#xD;
&#xD;
          8. Subject agrees to not participate in any other investigational or invasive clinical&#xD;
             study for a period of 5 years following the index procedure.&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
        Treatment of up to three de novo lesions in a maximum of two epicardial vessels, with a&#xD;
        maximum of two lesions per epicardial vessel. If only a single lesion is to be treated, it&#xD;
        must be a target lesion. Up to one non-target lesion can be treated. Non-target lesion&#xD;
        treatment can occur only in a non-target vessel.&#xD;
&#xD;
        If there are two target lesions within the same epicardial vessel, the two target lesions&#xD;
        must be at least 15 mm apart per visual estimation; otherwise this is considered as a&#xD;
        single target lesion for lesion (and stent) length determination and must be treated with a&#xD;
        single study device.&#xD;
&#xD;
        1. Target lesion(s) must be located in a native coronary artery with a visually estimated&#xD;
        or quantitatively assessed %DS of ≥50% and &lt; 100%, with a thrombolysis in myocardial&#xD;
        infarction (TIMI) flow of ≥ 1, and one of the following: stenosis ≥ 70%, an abnormal&#xD;
        functional test (e.g., fractional flow reserve ≤0.80 AND/OR a positive stress test), or&#xD;
        presentation with an acute coronary syndrome (unstable angina or NSTEMI within 2 weeks of&#xD;
        index procedure, or STEMI &gt;72 hours but ≤ 2 weeks prior to the index procedure).&#xD;
&#xD;
          1. Target lesion(s) must be located in a native coronary artery with reference vessel&#xD;
             diameter (RVD) by visual estimation of ≥ 2.50 mm and ≤ 3.75 mm.&#xD;
&#xD;
          2. Target lesion(s) must be located in a native coronary artery with length by visual&#xD;
             estimation of ≤ 24 mm.&#xD;
&#xD;
        Note: Subjects with Unstable angina (UA) or NSTEMI or STEMI occurring &gt; 2 weeks of the&#xD;
        index procedure can be included in the trial but should be categorized based on their&#xD;
        current angina class.&#xD;
&#xD;
        Note: To exclude enrollment of excessively small vessels, if the operator believes that&#xD;
        based on visual angiographic assessments, the distal reference vessel diameter is ≤ 2.75 mm&#xD;
        such that the plan is to implant a 2.5 mm device (stent or scaffold) in a target lesion, it&#xD;
        is strongly recommended that either on-line QCA or intravascular imaging (ultrasound or&#xD;
        optical coherence tomography) is used and demonstrates that the measured distal RVD for&#xD;
        this target lesion is ≥ 2.50 mm (by at least one of these imaging modalities). This&#xD;
        measurement may be performed before or after pre-dilatation, but before randomization. If&#xD;
        the distal RVD measures &lt;2.5 mm, that lesion IS NOT ELIGIBLE for randomization. Such a&#xD;
        lesion may be treated as a non-target lesion.&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          1. Any surgery requiring general anesthesia or discontinuation of aspirin and/or a P2Y12&#xD;
             receptor inhibitor is planned within 12 months after the procedure.&#xD;
&#xD;
          2. Subject has known hypersensitivity or contraindication to device material and its&#xD;
             degradants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and&#xD;
             cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot&#xD;
             be adequately pre-medicated. Subject has a known contrast sensitivity that cannot be&#xD;
             adequately pre-medicated.&#xD;
&#xD;
          3. Subject has known allergic reaction, hypersensitivity or contraindication to any of&#xD;
             the following: aspirin; or clopidogrel and prasugrel and ticagrelor; or heparin and&#xD;
             bivalirudin, and therefore cannot be adequately treated with study medications.&#xD;
&#xD;
          4. Subject had an acute STEMI (appropriate clinical syndrome with ≥1 mm of ST-segment&#xD;
             elevation in ≥2 contiguous leads) within 72 hours of the index procedure.&#xD;
&#xD;
          5. Subject has a cardiac arrhythmia identified at the time of screening for which at&#xD;
             least one of the following criteria is met:&#xD;
&#xD;
               1. Subject requires coumadin or any other agent for chronic oral anticoagulation.&#xD;
&#xD;
               2. Subject is likely to become hemodynamically unstable due to their arrhythmia.&#xD;
&#xD;
               3. Subject has poor survival prognosis due to their arrhythmia.&#xD;
&#xD;
          6. Subject has a left ventricular ejection fraction (LVEF) &lt; 30% assessed by any&#xD;
             quantitative method, including but not limited to echocardiography, MRI,&#xD;
             multiple-gated acquisition (MUGA) scan, contrast left ventriculography, PET scan, etc.&#xD;
             LVEF may be obtained within 6 months prior to the procedure for subjects with stable&#xD;
             CAD. For subjects presenting with acute coronary syndrome (ACS), LVEF must be assessed&#xD;
             within 1 week of the index procedure and after ACS presentation, which may include&#xD;
             contrast left ventriculography during the index procedure but prior to randomization&#xD;
             in order to confirm the subject's eligibility.&#xD;
&#xD;
          7. Subject has undergone prior PCI within the target vessel during the last 12 months.&#xD;
             Prior PCI within the non-target vessel or any peripheral intervention is acceptable if&#xD;
             performed anytime &gt;30 days before the index procedure, or between a minimum of 24&#xD;
             hours and 30 days before the index procedure if successful and uncomplicated.&#xD;
&#xD;
          8. Subject requires future staged PCI of any lesion other than a target lesion identified&#xD;
             at the time of index procedure; or subject requires future peripheral vascular&#xD;
             interventions &lt; 30 days after the index procedure.&#xD;
&#xD;
          9. Subject has received any solid organ transplants or is on a waiting list for any solid&#xD;
             organ transplants.&#xD;
&#xD;
         10. At the time of screening, the subject has a malignancy that is not in remission.&#xD;
&#xD;
         11. Subject is receiving immunosuppressant therapy or has known immunosuppressive or&#xD;
             severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human&#xD;
             immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are&#xD;
             not included as immunosuppressant therapy.&#xD;
&#xD;
         12. Subject has previously received or is scheduled to receive radiotherapy to a coronary&#xD;
             artery (vascular brachytherapy), or the chest/mediastinum.&#xD;
&#xD;
         13. Subject is receiving or will require chronic anticoagulation therapy (e.g., coumadin,&#xD;
             dabigatran, apixaban, rivaroxaban, edoxaban or any other related agent for any&#xD;
             reason).&#xD;
&#xD;
         14. Subject has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3.&#xD;
&#xD;
         15. Subject has a documented or suspected hepatic disorder as defined as cirrhosis or&#xD;
             Child-Pugh ≥ Class B.&#xD;
&#xD;
         16. Subject has renal insufficiency as defined as an estimated glomerular filtration rate&#xD;
             (GFR) &lt; 30 ml/min/1.73m2 or dialysis at the time of screening.&#xD;
&#xD;
         17. Subject is high risk of bleeding for any reason; has a history of bleeding diathesis&#xD;
             or coagulopathy; has had a significant gastrointestinal or significant urinary bleed&#xD;
             within the past six months.&#xD;
&#xD;
         18. Subject has had a cerebrovascular accident or transient ischemic neurological attack&#xD;
             (TIA) within the past six months, or any prior intracranial bleed, or any permanent&#xD;
             neurologic defect, or any known intracranial pathology (e.g. aneurysm, arteriovenous&#xD;
             malformation, etc.).&#xD;
&#xD;
         19. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath&#xD;
             insertion. Note: femoral arterial disease does not exclude the patient if radial&#xD;
             access may be used.&#xD;
&#xD;
         20. Subject has a life expectancy &lt;5 years for any non-cardiac or cardiac cause.&#xD;
&#xD;
         21. Subject is in the opinion of the Investigator or designee, unable to comply with the&#xD;
             requirements of the study protocol or is unsuitable for the study for any reason. This&#xD;
             includes completion of Patient Reported Outcome instruments.&#xD;
&#xD;
         22. Subject is currently participating in another clinical trial that has not yet&#xD;
             completed its primary endpoint.&#xD;
&#xD;
         23. Subject is part of a vulnerable population who, in the judgment of the investigator,&#xD;
             is unable to give Informed Consent for reasons of incapacity, immaturity, adverse&#xD;
             personal circumstances or lack of autonomy. This may include: Individuals with a&#xD;
             mental disability, persons in nursing homes, children, impoverished persons, persons&#xD;
             in emergency situations, homeless persons, nomads, refugees, and those incapable of&#xD;
             giving informed consent. Vulnerable populations also may include members of a group&#xD;
             with a hierarchical structure such as university students, subordinate hospital and&#xD;
             laboratory personnel, employees of the Sponsor, members of the armed forces, and&#xD;
             persons kept in detention.&#xD;
&#xD;
        Angiographic Exclusion Criteria:&#xD;
&#xD;
        All exclusion criteria apply to the target lesion(s) or target vessel(s).&#xD;
&#xD;
          1. Unsuccessful pre-dilatation, defined as the presence of one or more of the following&#xD;
             (note: successful pre-dilatation of at least one target lesion is required prior to&#xD;
             randomization):&#xD;
&#xD;
               1. Residual %diameter stenosis (DS) after pre-dilatation is ≥ 40% (per visual&#xD;
                  estimation). Note: achieving a %DS ≤ 20% prior to randomization is strongly&#xD;
                  recommended.&#xD;
&#xD;
               2. TIMI flow grade &lt;3 (per visual estimation).&#xD;
&#xD;
               3. Any angiographic complication (e.g. distal embolization, side branch closure).&#xD;
&#xD;
               4. Any dissection NHLBI grade D-F.&#xD;
&#xD;
               5. Any chest pain lasting &gt; 5 minutes.&#xD;
&#xD;
               6. Any ST-segment depression or elevation lasting &gt; 5 minutes.&#xD;
&#xD;
          2. Lesion is located in left main or there is a ≥30% diameter stenosis in the left main&#xD;
             (unless the left main lesion is a protected left main (i.e. a patent bypass graft to&#xD;
             the LAD and/or LCX arteries is present), and there is no intention to treat the&#xD;
             protected left main lesion).&#xD;
&#xD;
          3. Aorto-ostial right coronary artery (RCA) lesion (within 3 mm of the ostium).&#xD;
&#xD;
          4. Lesion located within 3 mm of the origin of the left anterior descending artery (LAD)&#xD;
             or left circumflex artery (LCX).&#xD;
&#xD;
          5. Lesion involving a bifurcation with a:&#xD;
&#xD;
               1. side branch ≥ 2 mm in diameter, or&#xD;
&#xD;
               2. side branch with either an ostial or non-ostial lesion with diameter stenosis&#xD;
                  &gt;50%, or&#xD;
&#xD;
               3. side branch requiring dilatation&#xD;
&#xD;
          6. Anatomy proximal to or within the lesion that may impair delivery of the Absorb BVS or&#xD;
             XIENCE stent:&#xD;
&#xD;
               1. Extreme angulation (≥ 90°) proximal to or within the target lesion.&#xD;
&#xD;
               2. Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion.&#xD;
&#xD;
               3. Moderate or heavy calcification proximal to or within the target lesion. If&#xD;
                  intravascular ultrasound (IVUS) used, subject must be excluded if calcium arc in&#xD;
                  the vessel prior to the lesion or within the lesion is ≥ 180°.&#xD;
&#xD;
          7. Lesion or vessel involves a myocardial bridge.&#xD;
&#xD;
          8. Vessel has been previously treated with a stent and the target lesion is within 5 mm&#xD;
             proximal or distal to a previously stented lesion.&#xD;
&#xD;
          9. Target lesion located within an arterial or saphenous vein graft or distal to any&#xD;
             arterial or saphenous vein graft.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregg W Stone, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University Medical Center, New York, NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregg W Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University Medical Center, New York, NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen G Ellis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic, Cleveland OH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dean J Kereiakes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christ Hospital, Cincinnati, OH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chandler Regional Medical Center</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Gilbert Medical Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85297</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Muir Health Concord</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Memorial Hospital La Jolla</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Of California Davis Med Ctr</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Memorial Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Company Of Mary Hospital</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of the Rockies</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Memorial Hospital</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkhart General Hospital</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan St Francis Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Kentucky Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harper University Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St John Hospital &amp; Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Michigan Hospital</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boone Hospital Center/ Missouri Cardiovascular Specialists, LLP</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Patrick Hospital</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Heart Institute Heart Hosp.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Health Bergan Mercy</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady of Lourdes Medical Center</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Englewood Hospital and Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NewYork-Presbyterian/Queens</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYP Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester General Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital Health Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center-Northeast</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health Heart &amp; Vascular Institute/Presbyterian Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center-Pineville</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rex Hospital, Inc.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WakeMed</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Hospital</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy St. Vincent Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Hospital</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integris Baptist Medical Center, Inc.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Spirit Hospital</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doylestown Hospital</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health Hospitals</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17105-8700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forbes Hospital</name>
      <address>
        <city>Monroeville</city>
        <state>Pennsylvania</state>
        <zip>15146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upmc Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Medical Center</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anmed Health Medical Center</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Hospital</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont Holston Valley Medical Center</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Texas Healthcare System</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seton Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Heart and Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Texas Medical Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carilion Roanoke Memorial Hospital</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winchester Medical Center</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Reg Med Ctr Everett</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medstar Health Research Institute/ Medstar Washington Hospital Center</name>
      <address>
        <city>Northwest</city>
        <state>Washington</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6001</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM-Hotel Dieu</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Oberallgau gGmbH</name>
      <address>
        <city>Immenstadt</city>
        <state>Bavaria</state>
        <zip>87509</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kempten, Klinikverbund Kempten-Oberallgaeu gGmbH</name>
      <address>
        <city>Kempten-Allgau</city>
        <state>Bavaria</state>
        <zip>87439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Immanuel Klinikum Bernau Herzzentrum Brandenburg</name>
      <address>
        <city>Bernau</city>
        <state>Berlin</state>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Giessen</name>
      <address>
        <city>Giessen</city>
        <state>Hesse</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <state>Lower Saxony</state>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <state>North Rhine-Westphalia</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth-Krankenhaus</name>
      <address>
        <city>Essen</city>
        <state>North Rhine-Westphalia</state>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg-Universitaet</name>
      <address>
        <city>Mainz</city>
        <state>Rhineland-Palatinate</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segeberger Kliniken GmbH - Herzzentrum</name>
      <address>
        <city>Bad Segeberg</city>
        <state>Schleswig-Holstein</state>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Centre, Singapore, Pte, Ltd.</name>
      <address>
        <city>Singapore</city>
        <zip>169609</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 9, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <results_first_submitted>April 20, 2018</results_first_submitted>
  <results_first_submitted_qc>June 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 24, 2018</results_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Absorb™ BVS</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Bioabsorbable</keyword>
  <keyword>BVS</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary Artery Endothelial Responsiveness</keyword>
  <keyword>Coronary artery restenosis</keyword>
  <keyword>Coronary artery stenosis</keyword>
  <keyword>Coronary scaffold</keyword>
  <keyword>Coronary Stent</keyword>
  <keyword>Drug eluting stents</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Myocardial ischemia</keyword>
  <keyword>Stent thrombosis</keyword>
  <keyword>Stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT02173379/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT02173379/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 2604 subjects were randomized at 147 sites between August 15, 2014 and March 31, 2017. The last 1-year follow-up visit occurred on March 31, 2018. The database was then cleaned and locked, and data extraction for the 2-year analysis occurred on June 04, 2019.</recruitment_details>
      <pre_assignment_details>The last 2-year follow-up visit occurred on 16 April, 2019.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Absorb BVS</title>
          <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
        </group>
        <group group_id="P2">
          <title>XIENCE</title>
          <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1296"/>
                <participants group_id="P2" count="1308"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1205"/>
                <participants group_id="P2" count="1231"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Absorb BVS</title>
          <description>Subjects receiving public) Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
        </group>
        <group group_id="B2">
          <title>XIENCE</title>
          <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1296"/>
            <count group_id="B2" value="1308"/>
            <count group_id="B3" value="2604"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1296"/>
                    <count group_id="B2" value="1308"/>
                    <count group_id="B3" value="2604"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.1" spread="10.1"/>
                    <measurement group_id="B2" value="62.2" spread="10.3"/>
                    <measurement group_id="B3" value="62.65" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1296"/>
                    <count group_id="B2" value="1308"/>
                    <count group_id="B3" value="2604"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="369"/>
                    <measurement group_id="B2" value="361"/>
                    <measurement group_id="B3" value="730"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="927"/>
                    <measurement group_id="B2" value="947"/>
                    <measurement group_id="B3" value="1874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1296"/>
                    <count group_id="B2" value="1308"/>
                    <count group_id="B3" value="2604"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1256"/>
                    <measurement group_id="B2" value="1279"/>
                    <measurement group_id="B3" value="2535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1296"/>
                    <count group_id="B2" value="1308"/>
                    <count group_id="B3" value="2604"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1135"/>
                    <measurement group_id="B2" value="1160"/>
                    <measurement group_id="B3" value="2295"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1296"/>
                    <count group_id="B2" value="1308"/>
                    <count group_id="B3" value="2604"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1296"/>
                    <count group_id="B2" value="1308"/>
                    <count group_id="B3" value="2604"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1021"/>
                    <measurement group_id="B2" value="1041"/>
                    <measurement group_id="B3" value="2062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1296"/>
                    <count group_id="B2" value="1308"/>
                    <count group_id="B3" value="2604"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1296"/>
                    <count group_id="B2" value="1308"/>
                    <count group_id="B3" value="2604"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1296"/>
                    <count group_id="B2" value="1308"/>
                    <count group_id="B3" value="2604"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Coronary Intervention</title>
          <population>The number of participants analyzed includes subjects who were available at that time of analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1294"/>
                    <count group_id="B2" value="1307"/>
                    <count group_id="B3" value="2601"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="390"/>
                    <measurement group_id="B2" value="435"/>
                    <measurement group_id="B3" value="825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Target Lesion Failure (TLF)</title>
        <description>Target lesion failure (TLF) composite of Cardiac Death, Myocardial Infarction attributable to Target Vessel (TV-MI), or Ischemia-Driven Target Lesion Revascularization (ID-TLR))</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Failure (TLF)</title>
          <description>Target lesion failure (TLF) composite of Cardiac Death, Myocardial Infarction attributable to Target Vessel (TV-MI), or Ischemia-Driven Target Lesion Revascularization (ID-TLR))</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis test is designed to show non-inferiority of Absorb BVS to XIENCE for the primary endpoint with a one-sided alpha of 0.025. The null (H0) and alternative (HA) hypotheses are:&#xD;
H0: TLFAbsorb - TLFXIENCE ≥ ∆TLF HA: TLFAbsorb - TLFXIENCE &lt; ∆TLF.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>One-sided p-value by using Farrington-Manning non-inferiority test statistic with non-inferiority margin of 2.9%, to be compared with a one-sided significance level of 0.025.</non_inferiority_desc>
            <p_value>0.0244</p_value>
            <method>Farrington-Manning</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TLF at 1-year, Non-inferiority Against the Control</title>
        <description>One-sided p-value by using Farrington-Manning non-inferiority test will be used with non-inferiority margin of 4.8%, to be compared with a one-sided significance level of 0.025.</description>
        <time_frame>1 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>TLF at 1-year, Non-inferiority Against the Control</title>
          <description>One-sided p-value by using Farrington-Manning non-inferiority test will be used with non-inferiority margin of 4.8%, to be compared with a one-sided significance level of 0.025.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1254"/>
                <count group_id="O2" value="1272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>One-sided p-value by using Farrington-Manning non-inferiority test statistic with non-inferiority margin of 4.8%, to be compared with a one-sided significance level of 0.025.</non_inferiority_desc>
            <p_value>0.0006</p_value>
            <method>Farrington-Manning</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angina at 1-year, Non-inferiority Against the Control</title>
        <description>Angina is defined as any angina or angina equivalent symptoms determined by the physician and/or research coordinator after interview of the patient, and as adjudicated by a clinical events committee (CEC).&#xD;
This analysis will exclude angina or angina equivalent symptoms that occurred following the index procedure through hospital discharge or 7 days, whichever occurs first.</description>
        <time_frame>1 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Angina at 1-year, Non-inferiority Against the Control</title>
          <description>Angina is defined as any angina or angina equivalent symptoms determined by the physician and/or research coordinator after interview of the patient, and as adjudicated by a clinical events committee (CEC).&#xD;
This analysis will exclude angina or angina equivalent symptoms that occurred following the index procedure through hospital discharge or 7 days, whichever occurs first.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1249"/>
                <count group_id="O2" value="1261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253"/>
                    <measurement group_id="O2" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Target Lesion With Acute Success- Device Success (Lesion Level Analysis)</title>
        <description>Successful delivery and deployment of the study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 30% by quantitative coronary angiography (QCA) (by visual estimation if QCA unavailable). When bailout scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment is not one of the criteria for device success.</description>
        <time_frame>In-hospital (≤ 7days)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Target Lesion With Acute Success- Device Success (Lesion Level Analysis)</title>
          <description>Successful delivery and deployment of the study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 30% by quantitative coronary angiography (QCA) (by visual estimation if QCA unavailable). When bailout scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment is not one of the criteria for device success.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Percentage of target lesions</units>
          <param>Number</param>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1424"/>
                <count group_id="O2" value="1450"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.6"/>
                    <measurement group_id="O2" value="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Success- Procedural Success (Subject Level Analysis)</title>
        <description>Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days).</description>
        <time_frame>In-hospital (≤ 7days)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Success- Procedural Success (Subject Level Analysis)</title>
          <description>Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1203"/>
                    <measurement group_id="O2" value="1250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>90 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1286"/>
                <count group_id="O2" value="1300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>180 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>270 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1264"/>
                <count group_id="O2" value="1279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>1 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1254"/>
                <count group_id="O2" value="1272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>2 years</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1232"/>
                <count group_id="O2" value="1255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction (MI)</title>
          <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction (MI)</title>
          <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>90 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction (MI)</title>
          <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1286"/>
                <count group_id="O2" value="1300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>180 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction (MI)</title>
          <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>270 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction (MI)</title>
          <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1264"/>
                <count group_id="O2" value="1279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>1 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction (MI)</title>
          <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1254"/>
                <count group_id="O2" value="1272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>2 years</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction (MI)</title>
          <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1232"/>
                <count group_id="O2" value="1255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction (MI)</title>
        <description>Attributable to target vessel (TV-MI)&#xD;
Not attributable to target vessel (NTV-MI)</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
        <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
          <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
        <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
          <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
        <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
        <time_frame>90 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
          <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1286"/>
                <count group_id="O2" value="1300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
        <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
        <time_frame>180 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
          <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
        <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
        <time_frame>270 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
          <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1264"/>
                <count group_id="O2" value="1279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
        <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
        <time_frame>1 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
          <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1254"/>
                <count group_id="O2" value="1272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
        <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
        <time_frame>2 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
          <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1232"/>
                <count group_id="O2" value="1255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
        <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
        <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
        <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants withTarget Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>90 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants withTarget Lesion Revascularization (TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1286"/>
                <count group_id="O2" value="1300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>180 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>270 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1264"/>
                <count group_id="O2" value="1279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>1 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1254"/>
                <count group_id="O2" value="1272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>2 years</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1232"/>
                <count group_id="O2" value="1255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia Driven TLR (ID-TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia Driven TLR (ID-TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia Driven TLR (ID-TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia Driven TLR (ID-TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia Driven TLR (ID-TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
        <time_frame>90 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia Driven TLR (ID-TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1286"/>
                <count group_id="O2" value="1300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia Driven TLR (ID-TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
        <time_frame>180 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia Driven TLR (ID-TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia Driven TLR (ID-TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
        <time_frame>270 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia Driven TLR (ID-TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1264"/>
                <count group_id="O2" value="1279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia Driven TLR (ID-TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
        <time_frame>1 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia Driven TLR (ID-TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1254"/>
                <count group_id="O2" value="1272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia Driven TLR (ID-TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
        <time_frame>2 years</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia Driven TLR (ID-TLR)</title>
          <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1232"/>
                <count group_id="O2" value="1255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia Driven TLR (ID-TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia Driven TLR (ID-TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia Driven TLR (ID-TLR)</title>
        <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>90 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1286"/>
                <count group_id="O2" value="1300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. classified as: Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
-TVR includes all TVR, excluding TLR</description>
        <time_frame>180 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. classified as: Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
-TVR includes all TVR, excluding TLR</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>270 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1264"/>
                <count group_id="O2" value="1279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>1 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1254"/>
                <count group_id="O2" value="1272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>2 years</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1232"/>
                <count group_id="O2" value="1255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ID-TVR Excluding TLR</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ID-TVR Excluding TLR</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ID-TVR Excluding TLR</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ID-TVR Excluding TLR</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ID-TVR Excluding TLR</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>90 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ID-TVR Excluding TLR</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1286"/>
                <count group_id="O2" value="1300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ID-TVR Excluding TLR</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>180 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ID-TVR Excluding TLR</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ID-TVR Excluding TLR</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>270 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ID-TVR Excluding TLR</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1264"/>
                <count group_id="O2" value="1279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ID-TVR Excluding TLR</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>1 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ID-TVR Excluding TLR</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1254"/>
                <count group_id="O2" value="1272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ID-TVR Excluding TLR</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>2 years</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ID-TVR Excluding TLR</title>
          <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1232"/>
                <count group_id="O2" value="1255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ID-TVR Excluding TLR</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ID-TVR Excluding TLR</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ID-TVR Excluding TLR</title>
        <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.&#xD;
TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.&#xD;
TVR includes all TVR, excluding TLR</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization</title>
          <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization</title>
          <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>90 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization</title>
          <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1286"/>
                <count group_id="O2" value="1300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>180 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization</title>
          <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>270 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization</title>
          <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1264"/>
                <count group_id="O2" value="1279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>1 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization</title>
          <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1254"/>
                <count group_id="O2" value="1272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>2 years</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization</title>
          <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1232"/>
                <count group_id="O2" value="1255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Revascularization includes TLR, TVR excluding TLR, and non TVR.</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced All Death/All MI</title>
        <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced All Death/All MI</title>
          <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced All Death/All MI</title>
        <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced All Death/All MI</title>
          <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced All Death/All MI</title>
        <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>90 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced All Death/All MI</title>
          <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1286"/>
                <count group_id="O2" value="1300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced All Death/All MI</title>
        <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>180 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced All Death/All MI</title>
          <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced All Death/All MI</title>
        <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>270 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced All Death/All MI</title>
          <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1264"/>
                <count group_id="O2" value="1279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced All Death/All MI</title>
        <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>1 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced All Death/All MI</title>
          <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1254"/>
                <count group_id="O2" value="1272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced All Death/All MI</title>
        <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>2 years</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced All Death/All MI</title>
          <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1232"/>
                <count group_id="O2" value="1255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced All Death/All MI</title>
        <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced All Death/All MI</title>
        <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced All Death/All MI</title>
        <description>All deaths includes&#xD;
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.&#xD;
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.&#xD;
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.&#xD;
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.&#xD;
-Non-Q wave MI: Those MIs which are not Q-wave MI</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI</title>
          <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI</title>
          <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>90 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI</title>
          <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1286"/>
                <count group_id="O2" value="1300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>180 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI</title>
          <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>270 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI</title>
          <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1264"/>
                <count group_id="O2" value="1279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>1 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI</title>
          <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1254"/>
                <count group_id="O2" value="1272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>2 years</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI</title>
          <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1232"/>
                <count group_id="O2" value="1255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI</title>
        <description>Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>90 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1286"/>
                <count group_id="O2" value="1300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>180 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>270 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1264"/>
                <count group_id="O2" value="1279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>1 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1254"/>
                <count group_id="O2" value="1272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>2 years</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1232"/>
                <count group_id="O2" value="1255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced With Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced With Cardiac Death/All MI/ID-TLR (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>90 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1286"/>
                <count group_id="O2" value="1300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>180 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>270 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1264"/>
                <count group_id="O2" value="1279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>1 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1254"/>
                <count group_id="O2" value="1272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>2 years</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1232"/>
                <count group_id="O2" value="1255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (Target Vessel Failure, TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (Target Vessel Failure, TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>90 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1286"/>
                <count group_id="O2" value="1300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>180 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>270 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1264"/>
                <count group_id="O2" value="1279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>1 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1254"/>
                <count group_id="O2" value="1272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>2 years</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
          <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1232"/>
                <count group_id="O2" value="1255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)</title>
        <description>Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>90 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1286"/>
                <count group_id="O2" value="1300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>180 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>270 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1264"/>
                <count group_id="O2" value="1279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>1 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1254"/>
                <count group_id="O2" value="1272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>2 years</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1232"/>
                <count group_id="O2" value="1255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experienced Death/All MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Scaffold/Stent Thrombosis (Per Academic Research Consortium (ARC) Definition)</title>
        <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
        <time_frame>0 - 24 hours post stent implantation</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Scaffold/Stent Thrombosis (Per Academic Research Consortium (ARC) Definition)</title>
          <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1291"/>
                <count group_id="O2" value="1305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Subacute Scaffold/Stent Thrombosis (Per ARC Definition)</title>
        <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
        <time_frame>&gt;24 hours - 30 days post stent implantation</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Subacute Scaffold/Stent Thrombosis (Per ARC Definition)</title>
          <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1287"/>
                <count group_id="O2" value="1301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Late Scaffold/Stent Thrombosis (Per ARC Definition)</title>
        <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
        <time_frame>30 days - 1 year post stent implantation</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Late Scaffold/Stent Thrombosis (Per ARC Definition)</title>
          <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1238"/>
                <count group_id="O2" value="1258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cumulative Scaffold/Stent Thrombosis (Per ARC Definition)</title>
        <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained</description>
        <time_frame>0 to 730 Days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cumulative Scaffold/Stent Thrombosis (Per ARC Definition)</title>
          <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1210"/>
                <count group_id="O2" value="1231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rehospitalization</title>
        <description>Coronary artery disease (CAD) related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Rehospitalization</title>
          <description>Coronary artery disease (CAD) related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rehospitalization</title>
        <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
        <time_frame>90 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Rehospitalization</title>
          <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1285"/>
                <count group_id="O2" value="1298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rehospitalization</title>
        <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
        <time_frame>180 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Rehospitalization</title>
          <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1283"/>
                <count group_id="O2" value="1290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                    <measurement group_id="O2" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rehospitalization</title>
        <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
        <time_frame>270 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Rehospitalization</title>
          <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1266"/>
                <count group_id="O2" value="1278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rehospitalization</title>
        <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
        <time_frame>1 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Rehospitalization</title>
          <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1254"/>
                <count group_id="O2" value="1271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276"/>
                    <measurement group_id="O2" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rehospitalization</title>
        <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
        <time_frame>2 years</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Rehospitalization</title>
          <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1238"/>
                <count group_id="O2" value="1254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="440"/>
                    <measurement group_id="O2" value="445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rehospitalization</title>
        <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rehospitalization</title>
        <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rehospitalization</title>
        <description>CAD related&#xD;
Cardiovascular, non-CAD related&#xD;
Non-cardiovascular related</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>In-hospital (≤ 7 days post index procedure)</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Repeat Coronary Arteriography</title>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1290"/>
                <count group_id="O2" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>30 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Repeat Coronary Arteriography</title>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1288"/>
                <count group_id="O2" value="1301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>90 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Repeat Coronary Arteriography</title>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1282"/>
                <count group_id="O2" value="1295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>180 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Repeat Coronary Arteriography</title>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1279"/>
                <count group_id="O2" value="1283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>270 days</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Repeat Coronary Arteriography</title>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1260"/>
                <count group_id="O2" value="1270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>1 year</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Repeat Coronary Arteriography</title>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1242"/>
                <count group_id="O2" value="1260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>2 years</time_frame>
        <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS</title>
            <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE</title>
            <description>Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Repeat Coronary Arteriography</title>
          <population>ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1218"/>
                <count group_id="O2" value="1236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Repeat Coronary Arteriography</title>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Landmark Analysis on MACE and TVF and Their Components</title>
        <time_frame>3-4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Landmark Analysis on MACE and TVF and Their Components</title>
        <time_frame>3-5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</title>
        <time_frame>3-4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Landmark Analysis on Scaffold Thrombosis/Stent Thrombosis (Per ARC Definition, Definite and Probable)</title>
        <time_frame>3-5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Failure (TLF)</title>
        <description>The analysis will be based on 4610 subjects (2000 primary analysis subjects of ABSORB III and 2610 subjects of ABSORB IV)</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes</title>
        <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.&#xD;
The following questionnaires will be used in this study:&#xD;
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life&#xD;
EuroQoL 5D (EQ-5D) survey to assess overall health status&#xD;
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)&#xD;
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.&#xD;
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
        <time_frame>Baseline</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes</title>
        <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.&#xD;
The following questionnaires will be used in this study:&#xD;
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life&#xD;
EuroQoL 5D (EQ-5D) survey to assess overall health status&#xD;
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)&#xD;
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.&#xD;
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
        <time_frame>1 month</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes</title>
        <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.&#xD;
The following questionnaires will be used in this study:&#xD;
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life&#xD;
EuroQoL 5D (EQ-5D) survey to assess overall health status&#xD;
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)&#xD;
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.&#xD;
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
        <time_frame>6 months</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes</title>
        <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.&#xD;
The following questionnaires will be used in this study:&#xD;
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life&#xD;
EuroQoL 5D (EQ-5D) survey to assess overall health status&#xD;
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)&#xD;
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.&#xD;
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes</title>
        <description>Patient-reported outcomes are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.&#xD;
The following questionnaires will be used in this study:&#xD;
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life&#xD;
EuroQoL 5D (EQ-5D) survey to assess overall health status&#xD;
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)&#xD;
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.&#xD;
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
        <time_frame>3 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Reported Outcomes (PRO)</title>
        <description>Patient-reported outcomes (PRO) are informational endpoints to assess Health-Related Quality of Life. PRO assessments will be conducted at baseline, 1 and 6 months, and at 1, 3 and 5 years.&#xD;
The following questionnaires will be used in this study:&#xD;
Seattle Angina Questionnaire-7 (SAQ-7) to assess disease-specific Quality of Life&#xD;
EuroQoL 5D (EQ-5D) survey to assess overall health status&#xD;
(Note: PRO endpoints will be evaluated in the ~2610 subjects of ABSORB IV)&#xD;
The PROs will be analyzed to evaluate the relationship between quality of life and cardiovascular events that occurred post-PCI and to substantiate the clinical impact of the angina events identified in the trial.&#xD;
Assessments are made at all time points listed. But overall analysis of QoL is planned to be conducted at the end of the trial.</description>
        <time_frame>5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Landmark Analysis on TLF and Components</title>
        <description>TLF is defined as composite of Cardiac Death, Myocardial Infarction (MI) attributable to Target Vessel (TV-MI), or Ischemia- Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>3-4 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Landmark Analysis on TLF and Components</title>
        <description>TLF is defined as composite of Cardiac Death, Myocardial Infarction (MI) attributable to Target Vessel (TV-MI), or Ischemia- Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>3-5 years</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Absorb BVS</title>
          <description>Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS)</description>
        </group>
        <group group_id="E2">
          <title>XIENCE</title>
          <description>Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="637" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="588" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NORMOCHROMIC NORMOCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ACUTE LEFT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIOSPASM CORONARY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK SECOND DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK LEFT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHRONOTROPIC INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONGESTIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE HEART DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTROPHIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IN-STENT CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTRACARDIAC THROMBUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MYOPERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PRINZMETAL ANGINA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>CONGENITAL ARTERIAL MALFORMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORNEAL DYSTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PHIMOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VERTIGO POSITIONAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>CARCINOID SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GOITRE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERPARATHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THYROID MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MACULAR FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RETINAL ARTERY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TOLOSA-HUNT SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BARRETT'S OESOPHAGUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COLITIS ULCERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COLONIC POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CROHN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DENTAL CARIES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS INTESTINAL HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FAECALOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTRITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HIATUS HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IMPAIRED GASTRIC EMPTYING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTESTINAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MALLORY-WEISS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PANCREATITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SPIGELIAN HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VOLVULUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC COMPLICATION ASSOCIATED WITH DEVICE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COMPLICATION OF DEVICE REMOVAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEVICE FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEVICE ISSUE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEVICE LEAD DAMAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEVICE MALFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EARLY SATIETY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FACIAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THROMBOSIS IN DEVICE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE HEPATIC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BILE DUCT OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GALLBLADDER DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC HEPATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ABSCESS NECK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ABSCESS ORAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS GRAFT SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTHRITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BACTERIAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BRONCHITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIABETIC FOOT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EMPYEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EXTRADURAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INFECTIOUS PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LABYRINTHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIVER ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION PSEUDOMONAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NECROTISING FASCIITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TOOTH INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VIRAL LABYRINTHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACETABULUM FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTHROPOD STING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BACK INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC PROCEDURE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COMMINUTED FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONFUSION POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FOREARM FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL STOMA COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAND FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEAT EXHAUSTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IN-STENT ARTERIAL RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IN-STENT CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIGAMENT RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PATELLA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PELVIC ORGAN INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERIPROSTHETIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PLAQUE SHIFT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POISONING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POISONING DELIBERATE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST-TRAUMATIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>STAB WOUND</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THORACIC VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TRAUMATIC HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TRAUMATIC INTRACRANIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TRAUMATIC LUNG INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VASCULAR GRAFT COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VASCULAR GRAFT OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ARTERIOGRAM CORONARY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE MB INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC ENZYMES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC STRESS TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EJECTION FRACTION DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GLYCOSYLATED HAEMOGLOBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TROPONIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LACTIC ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OBESITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CERVICAL SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COSTOCHONDRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FOOT DEFORMITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OSTEOCHONDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RHABDOMYOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SPINAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TENDONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VERTEBRAL FORAMINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACUTE PROMYELOCYTIC LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>B-CELL LYMPHOMA STAGE I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>B-CELL LYMPHOMA STAGE IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BENIGN SOFT TISSUE NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BILE DUCT CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BOWEN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BREAST CANCER IN SITU</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BREAST CANCER STAGE II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COLON ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL STROMAL TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT RECURRENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTESTINAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MALIGNANT GLIOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MALIGNANT PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MANTLE CELL LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>METASTASES TO CENTRAL NERVOUS SYSTEM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUELLER'S MIXED TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MULTIPLE MYELOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MYELODYSPLASTIC SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NEUROENDOCRINE CARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NON-HODGKIN'S LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OVARIAN CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OVARIAN CANCER STAGE III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PARATHYROID TUMOUR BENIGN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PLASMACYTOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URETERIC CANCER RECURRENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BRAIN INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BRAIN MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARPAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CENTRAL NERVOUS SYSTEM LESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CEREBELLAR INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CERVICAL MYELOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CERVICOBRACHIAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COMPLICATED MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CUBITAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEPRESSED LEVEL OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EMBOLIC CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GRAND MAL CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>METABOLIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MULTIPLE SCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PARTIAL SEIZURES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RADICULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SENSORY LOSS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TYPICAL AURA WITHOUT HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ULNAR TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL WITHDRAWAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONVERSION DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEPRESSION SUICIDAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTENTIONAL SELF-INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST-TRAUMATIC AMNESTIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SOMATOFORM DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CYSTITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OBSTRUCTIVE UROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EPIDIDYMITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ERECTILE DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>UTERINE POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VAGINAL PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIAPHRAGMATIC PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ANGIOEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DRY GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PRECANCEROUS SKIN LESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SCAR PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>HIP ARTHROPLASTY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYSTERECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERCUTANEOUS CORONARY INTERVENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SPINAL FUSION SURGERY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SURGERY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ACCELERATED HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>AORTIC DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIAL THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EMBOLISM ARTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERIAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE EMERGENCY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTERMITTENT CLAUDICATION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MALIGNANT HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERIPHERAL VASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1110" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1097" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC DIATHESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NORMOCHROMIC NORMOCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SPLENIC GRANULOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ACUTE LEFT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="281" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="272" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIOSPASM CORONARY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK SECOND DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK LEFT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHRONOTROPIC INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONGESTIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CYANOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIASTOLIC DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEART VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE HEART DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTROPHIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IN-STENT CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTRACARDIAC THROMBUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MYOPERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NODAL ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PRINZMETAL ANGINA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RESTRICTIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SINUS ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SINUS BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SINUS TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TACHYARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VENTRICULAR ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERIOVENOUS MALFORMATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONGENITAL ARTERIAL MALFORMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORNEAL DYSTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYDROCELE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PHIMOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>CERUMEN IMPACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEAFNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEAFNESS UNILATERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EAR CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EAR HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EAR PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EUSTACHIAN TUBE DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NEUROSENSORY HYPOACUSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TYMPANIC MEMBRANE PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VERTIGO POSITIONAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ADRENAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARCINOID SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GOITRE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERPARATHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOGONADISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SECONDARY HYPOGONADISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THYROID MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>ABNORMAL SENSATION IN EYE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>AMAUROSIS FUGAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLINDNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLINDNESS TRANSIENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIABETIC RETINOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIPLOPIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DRY EYE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EYE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EYE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GLAUCOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LACRIMAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MACULAR DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MACULAR FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MACULAR OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OCULAR HYPERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RETINAL ARTERY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RETINAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RETINAL TEAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TOLOSA-HUNT SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VISUAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VITREOUS DETACHMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VITREOUS HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANAL FISSURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>APPENDIX DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BARRETT'S OESOPHAGUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BOWEL MOVEMENT IRREGULARITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COLITIS ULCERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COLONIC POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CROHN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DENTAL CARIES</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS INTESTINAL HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EPIGASTRIC DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ERUCTATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FAECALOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FAECES DISCOLOURED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FOOD POISONING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTRIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTRIC POLYPS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTRITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL MOTILITY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL MUCOSAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GINGIVAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HIATUS HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IMPAIRED GASTRIC EMPTYING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTESTINAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIP HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIP SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MALLORY-WEISS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MELANOSIS COLI</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MOUTH HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MOUTH ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ODYNOPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL HYPOMOTILITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL SPASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ORAL MUCOSAL DISCOLOURATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PANCREATITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA ORAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POLYP COLORECTAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCTITIS ULCERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RECTAL POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SPIGELIAN HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>STOMACH MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SWOLLEN TONGUE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TOOTH DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TOOTH LOSS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VOLVULUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>AXILLARY PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC COMPLICATION ASSOCIATED WITH DEVICE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE RELATED REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COMPLICATION OF DEVICE REMOVAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEVICE FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEVICE ISSUE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEVICE LEAD DAMAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEVICE MALFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEVICE OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DRUG INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EARLY SATIETY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FACIAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FEELING COLD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FEELING HOT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GENERALISED OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GRANULOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INFUSION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LOCAL SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="225" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PACEMAKER GENERATED ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PATIENT-DEVICE INCOMPATIBILITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SENSATION OF FOREIGN BODY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SPINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THROMBOSIS IN DEVICE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>UNEVALUABLE EVENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VESSEL PUNCTURE SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VESSEL PUNCTURE SITE THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE HEPATIC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BILE DUCT OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BILIARY DILATATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GALLBLADDER DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GRANULOMATOUS LIVER DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEPATIC CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEPATIC FUNCTION ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEPATIC LESION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEPATIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC HEPATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGY TO ARTHROPOD BITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ALLERGY TO ARTHROPOD STING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONTRAST MEDIA ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FOOD ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SARCOIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SEASONAL ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ABSCESS NECK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ABSCESS ORAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ACARODERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ACUTE SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS GRAFT SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTHRITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BACTERIAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BODY TINEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BRONCHITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BURSITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CAMPYLOBACTER INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHRONIC SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIABETIC FOOT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EMPYEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ENDOMETRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EPIDEMIC POLYARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EXTRADURAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FURUNCLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTRITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GENITAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HELICOBACTER INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HERPES SIMPLEX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IMPETIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INFECTED BITES</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INFECTED CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INFECTIOUS PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTERTRIGO CANDIDA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>KIDNEY INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LABYRINTHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIVER ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION PSEUDOMONAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LYME DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LYMPH GLAND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MYRINGITIS BULLOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NECROTISING FASCIITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ORAL FUNGAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ORCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OTITIS EXTERNA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PELVIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ESCHERICHIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SCROTAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SIALOADENITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SINOBRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SINUSITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SKIN INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TOOTH INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TRICHOMONIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VAGINITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VIRAL LABYRINTHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ACETABULUM FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANAEMIA POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANIMAL BITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTHROPOD BITE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTHROPOD STING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>AXILLARY NERVE INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BACK INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC PROCEDURE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COMMINUTED FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONFUSION POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONTRAST MEDIA ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORNEAL ABRASION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CRANIOCEREBRAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CYSTITIS RADIATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEPRESSION POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DRUG ADMINISTRATION ERROR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EAR INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EPICONDYLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EXCORIATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EXPOSURE TO TOXIC AGENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EYE PENETRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FOREARM FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL DISORDER POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL STOMA COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAND FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEAT EXHAUSTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IN-STENT ARTERIAL RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IN-STENT CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INCISION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INCORRECT DOSE ADMINISTERED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INJURY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIGAMENT RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIGAMENT SPRAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MOUTH INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCLE RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCLE STRAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PATELLA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PELVIC ORGAN INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERIPROSTHETIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PLAQUE SHIFT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POISONING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POISONING DELIBERATE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST-TRAUMATIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE FEVER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROCEDURAL VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SEROMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>STAB WOUND</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUTURE RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THORACIC VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TOOTH FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TRAUMATIC HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TRAUMATIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TRAUMATIC INTRACRANIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TRAUMATIC LUNG INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VASCULAR GRAFT COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VASCULAR GRAFT OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WOUND COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WOUND HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANGIOGRAM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIAL BRUIT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIOGRAM CORONARY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIOGRAM CORONARY ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD CHOLESTEROL DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD CHOLESTEROL INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE MB ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE MB DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE MB INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD LACTIC ACID INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD MAGNESIUM DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD POTASSIUM DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE SYSTOLIC DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE SYSTOLIC INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD TESTOSTERONE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD TRIGLYCERIDES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD URIC ACID INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLOOD URINE PRESENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC ENZYMES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="149" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC MURMUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC STRESS TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CAROTID BRUIT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATHETERISATION CARDIAC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COMPUTERISED TOMOGRAM THORAX ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EJECTION FRACTION DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ST SEGMENT ELEVATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FEMORAL BRUIT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FIBRIN D DIMER INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GLYCOSYLATED HAEMOGLOBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEART RATE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEART RATE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEART RATE IRREGULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INFLUENZA A VIRUS TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR END-DIASTOLIC PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIVER SCAN ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LOW DENSITY LIPOPROTEIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LYMPHOCYTE COUNT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MEAN CELL VOLUME ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OCCULT BLOOD POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OESOPHAGOGASTRODUODENOSCOPY ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OXYGEN SATURATION DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROSTATIC SPECIFIC ANTIGEN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>STRESS ECHOCARDIOGRAM ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TROPONIN I INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TROPONIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TROPONIN T INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ULTRASOUND THYROID ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>CARBOHYDRATE INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GLUCOSE TOLERANCE IMPAIRED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERCHOLESTEROLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTRIGLYCERIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERURICAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOVITAMINOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LACTIC ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>METABOLIC ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OBESITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VITAMIN B12 DEFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VITAMIN D DEFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CERVICAL SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHONDROMALACIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHONDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COSTOCHONDRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DUPUYTREN'S CONTRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EXOSTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FOOT DEFORMITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GROIN PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>JOINT EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>JOINT STIFFNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIMB DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MONARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCLE ATROPHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCLE TIGHTNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCLE TWITCHING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL STIFFNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NEUROPATHIC ARTHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OSTEOCHONDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OSTEOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PAIN IN JAW</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PLANTAR FASCIAL FIBROMATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PLANTAR FASCIITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PSORIATIC ARTHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RHABDOMYOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SCLERODERMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SPINAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SYNOVIAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TENDONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TRIGGER FINGER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VERTEBRAL FORAMINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACUTE PROMYELOCYTIC LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>B-CELL LYMPHOMA STAGE I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>B-CELL LYMPHOMA STAGE IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BENIGN BREAST NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BENIGN SOFT TISSUE NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BILE DUCT CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BOWEN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BREAST CANCER IN SITU</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BREAST CANCER STAGE II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COLON ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FIBROMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL STROMAL TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT RECURRENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTESTINAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIPOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MALIGNANT GLIOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MALIGNANT PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MANTLE CELL LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MENINGIOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>METASTASES TO CENTRAL NERVOUS SYSTEM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>METASTATIC RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MUELLER'S MIXED TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MULTIPLE MYELOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MYELODYSPLASTIC SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NEOPLASM SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NEUROENDOCRINE CARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NON-HODGKIN'S LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OVARIAN CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OVARIAN CANCER STAGE III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PANCREATIC NEUROENDOCRINE TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PARATHYROID TUMOUR BENIGN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PHAEOCHROMOCYTOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PITUITARY TUMOUR BENIGN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PLASMACYTOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SEBORRHOEIC KERATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SKIN CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THYROID NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URETERIC CANCER RECURRENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BASAL GANGLIA INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BASILAR ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BRAIN INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BRAIN MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARPAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CENTRAL NERVOUS SYSTEM LESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CEREBELLAR ATROPHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CEREBELLAR INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CERVICAL MYELOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CERVICOBRACHIAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COGNITIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COMPLICATED MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CUBITAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEMENTIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEPRESSED LEVEL OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIABETIC NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIZZINESS EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIZZINESS POSTURAL</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DRUG WITHDRAWAL HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSARTHRIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EMBOLIC CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FACIAL PARESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GRAND MAL CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEAD DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEAD TITUBATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTERCOSTAL NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LACUNAR INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUMBAR RADICULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>METABOLIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MULTIPLE SCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NERVE COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PARTIAL SEIZURES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RADIAL NERVE COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RADICULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RESTLESS LEGS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SENSORY LOSS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TYPICAL AURA WITHOUT HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ULNAR TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VIITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL WITHDRAWAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANORGASMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANXIETY DISORDER DUE TO A GENERAL MEDICAL CONDITION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CONVERSION DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEPRESSION SUICIDAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DISORIENTATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTENTIONAL SELF-INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PANIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERSONALITY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POST-TRAUMATIC AMNESTIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SLEEP DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SOMATOFORM DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>STRESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WITHDRAWAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>AZOTAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLADDER NECK OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BLADDER PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CALCULUS URINARY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CYSTITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTONIC BLADDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NOCTURIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OBSTRUCTIVE UROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POLLAKIURIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>POLYURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RENAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URETHRAL MEATUS STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY BLADDER POLYP</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY HESITATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINARY TRACT OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URINE FLOW DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ATROPHIC VULVOVAGINITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BREAST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CYSTOCELE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EPIDIDYMITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ERECTILE DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>GENITAL SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PENILE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROSTATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PROSTATOMEGALY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SCROTAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>UTERINE POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VAGINAL PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BRONCHITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DIAPHRAGMATIC PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSPNOEA AT REST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EMPHYSEMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NASAL SEPTUM DEVIATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OBSTRUCTIVE AIRWAYS DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PHARYNGEAL HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PULMONARY CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PULMONARY MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>REFLUX LARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RESTRICTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SINUS CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THROAT IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THROAT TIGHTNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VOCAL CORD POLYP</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>WHEEZING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACNE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ACTINIC KERATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANGIOEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DERMAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DERMATITIS CONTACT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DRUG ERUPTION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DRY GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ECCHYMOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INCREASED TENDENCY TO BRUISE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INGROWING NAIL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LICHEN SCLEROSUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>LIVEDO RETICULARIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>NIGHT SWEATS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PETECHIAE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PRECANCEROUS SKIN LESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PRURITUS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RASH GENERALISED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RASH MACULAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>RASH PRURITIC</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SCAR PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SKIN DISCOLOURATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SKIN FISSURES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SKIN LESION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SWELLING FACE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SYSTEMIC LUPUS ERYTHEMATOSUS RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>MENOPAUSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PHYSICAL ASSAULT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>TREATMENT NONCOMPLIANCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ABSCESS DRAINAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>BAKER'S CYST EXCISION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CARDIAC PACEMAKER BATTERY REPLACEMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>CATARACT OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FRACTURE REDUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HIP ARTHROPLASTY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYSTERECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MOLE EXCISION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERCUTANEOUS CORONARY INTERVENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF REPAIR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SPINAL FUSION SURGERY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>SURGERY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ACCELERATED HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>AORTIC DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>AORTIC INTRAMURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIAL SPASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIAL THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>EMBOLISM ARTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERIAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE EMERGENCY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ILIAC ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTERMITTENT CLAUDICATION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>INTRA-ABDOMINAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC LIMB PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MACROANGIOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>MALIGNANT HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERIPHERAL COLDNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>PERIPHERAL VASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>REPERFUSION INJURY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS SUPERFICIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VARICOSE VEIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VASOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VENOUS INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1308"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1308"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Siok Hwee Tan</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>408-571-9281</phone>
      <email>siokwee.tan@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

